Key facts
- • FDA-approved Type 2 diabetes only — weight loss is off-label use.
- • Cash list ~$968/mo — much cheaper than Wegovy ($1,349/mo) for same molecule.
- • Doses: 0.25 → 0.5 → 1.0 → 2.0 mg weekly subcutaneous.
- • Off-label weight loss: 6-12% loss at 2.0 mg over 52-68 weeks.
- • If you want weight loss → request Wegovy (FDA-approved indication, insurance covers).
Indications: T2D primary, weight loss off-label
FDA-approved Ozempic indications (2017 launch, expanded over years):
- Type 2 diabetes mellitus glycemic control
- Reduce major adverse cardiovascular events in adults with T2D + established cardiovascular disease (added 2020)
- Reduce risk of chronic kidney disease progression in T2D + CKD (added 2024 via FLOW trial)
Weight loss prescribing is off-label — legal under US prescribing autonomy, but insurance generally won't cover off-label uses. Prescribers increasingly direct pure weight-loss patients to Wegovy (FDA-approved indication) or Zepbound vs Ozempic to avoid insurance denial loop.
Cost landscape
| Path | Cost |
|---|---|
| Cash list (no insurance) | ~$968/mo |
| Commercial insurance T2D copay | $25-50/mo typical |
| NovoCare patient assistance T2D | $0-25/mo qualified |
| Medicare Part D (T2D) | $0-100/mo with IRA $2,100 cap |
| Compounded semaglutide (similar molecule) | $99-296/mo |
| Off-label weight loss (no insurance) | Full ~$968/mo list |
Dose schedule
- Weeks 1-4: 0.25 mg weekly — initiation, monitor GI tolerance.
- Weeks 5-8: 0.5 mg weekly — maintenance for some T2D patients.
- Weeks 9-12: 1.0 mg weekly — full glycemic control dose for most.
- Weeks 13+: 2.0 mg weekly — max dose, primarily for additional weight reduction + cardiovascular benefit.
Titration 12-16 weeks. Skipping steps not recommended (GI side effects).
Ozempic vs Wegovy head-to-head
| Factor | Ozempic | Wegovy |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide (same molecule) |
| FDA indication | Type 2 diabetes | Chronic weight management |
| Max dose | 2.0 mg weekly | 2.4 mg weekly |
| Cash list price | ~$968/mo | ~$1,349/mo |
| Weight loss (clinical) | ~6-12% (off-label) | 14.9% (STEP-1) |
| Insurance for weight loss | Rarely covered (off-label) | Often covered (on-label) |
Telehealth providers prescribing Ozempic
Per regulatory_status='fda_brand' filter — all our brand-only providers prescribe Ozempic:
- Ro Body — multi-drug formulary, labs included
- Hers/Hims — Novo Nordisk partnership
- LifeMD — cheapest insurance-friendly
- PlushCare — board-certified PCPs
FAQ
Is Ozempic FDA-approved for weight loss?
No. Ozempic (semaglutide 0.25-2.0 mg subcutaneous weekly) is FDA-approved for Type 2 diabetes only. Weight loss prescriptions are off-label — legal practice but insurance rarely covers off-label use. Wegovy is the FDA-approved weight-loss form of the same molecule (higher dose, 2.4 mg).
How much weight do you lose on Ozempic?
Off-label trials show ~6-12% body weight loss at 2.0 mg over 52-68 weeks. Less than Wegovy (14.9% in STEP-1) because Ozempic max dose 2.0 mg vs Wegovy 2.4 mg. SUSTAIN-FORTE compared 2.0 mg vs 1.0 mg for T2D and showed dose-dependent metabolic benefits including weight reduction.
What does Ozempic cost?
List price ~$968/mo cash without insurance. With commercial insurance (T2D indication): copay ~$25-50/mo typical. NovoCare patient assistance may bring cost to $0 for qualifying T2D patients. Off-label weight-loss use rarely covered by insurance — patients pay near-list price.
Ozempic vs Wegovy — same drug?
Same molecule (semaglutide), different doses + indications. Wegovy: 2.4 mg weekly, FDA-approved weight loss. Ozempic: 0.25-2.0 mg weekly, FDA-approved T2D. Same manufacturer (Novo Nordisk). Wegovy 14.9% weight loss vs Ozempic 6-12% (lower max dose). If you have T2D, Ozempic likely covered; pure weight loss, Wegovy proper indication.
Can I use Ozempic for weight loss specifically?
Legally yes (off-label prescribing is legal). Practically risky: insurance won't cover off-label use, supply periodically constrained (FDA acute shortage status changed multiple times 2023-2026), prescribers increasingly directing weight-loss patients to Wegovy or Zepbound instead. If goal is pure weight loss, request Wegovy.
Side effects?
Same GLP-1 class profile as Wegovy: nausea (~40%), diarrhea, constipation, vomiting, abdominal pain. FDA black-box warning thyroid C-cell tumors (rodent studies; human relevance unknown). Pancreatitis, gallbladder disease, kidney injury rare but documented. Discuss with prescriber.
Compounded "semaglutide" same as Ozempic?
Same active molecule but different supply chain. Compounded semaglutide is pharmacy-mixed (NOT Novo Nordisk-manufactured), not FDA-approved as finished product. Cheaper ($99-296/mo via Eden/Henry/etc.) but carries FDA enforcement risk. Henry/Eden providers prescribe compounded; Ro/Hers prescribe brand Ozempic.
Best telehealth for Ozempic?
For insured T2D patients: PlushCare, LifeMD, or Ro Body (strong insurance handling). For self-pay off-label weight loss: direct manufacturer through NovoCare. Compounded path (Eden/Henry) cheaper if accept FDA risk.
Bottom line
Ozempic is the T2D version of semaglutide — cheaper than Wegovy ($968 vs $1,349/mo cash) but off-label for weight loss. If your goal is pure weight loss, request Wegovy (insurance-covered + higher max dose). If you have T2D, Ozempic likely covered + still produces 6-12% weight reduction. Compare providers.
Sources
Editorial only — not medical advice. Pricing accurate as of 2026-06-05.